AVNS · Avanos Medical, Inc. · Stock research

Current Thesis

Resolved, not pending. American Industrial Partners completed the acquisition of Avanos Medical on 2026-07-27 at $25.00 per share in cash, an enterprise value of approximately $1.272 billion, and the common stock ceased trading on the NYSE the same day (AIP press release, 2026-07-27). The guided completion date in the prior note — no later than 2026-07-27 — arrived on schedule and the equity was extinguished into cash. The narrative is dead, dated 2026-07-27. That is the only one of the four site labels that fits: the listing structure is gone. The nuance a reader should carry is that it ended by completion at par, not by a failed narrative — the payoff was delivered exactly as contracted, and then the instrument stopped existing. Everything below is a closed record and a set of read-across facts, because there is no US-listed share to analyse.

Bullish and bearish views on Avanos Medical, Inc.

The model's bull view on Avanos Medical, Inc. (AVNS), in brief: the two failure modes that kill most sponsor deals never engaged. The bear view: There is nothing to trade. Regular-way NYSE trading in AVNS was suspended on 2026-07-27; the company requested delisting via Form 25 and is now a wholly owned subsidiary of A-AV Holdco I, Inc. Any AVNS quote still visible on a screen is a stale final print. The last reference… Both cases follow in full.

Bull Case

• the two failure modes that kill most sponsor deals never engaged.
• The path was dated and clean: all required regulatory clearances received 2026-07-02; stockholder approval 2026-07-22 with roughly 99.75% of votes cast in favour, representing about 74.96% of shares outstanding as of the 2026-06-18 record date; completion 2026-07-27.
• Operating results never became the pressure point: Q1 reported 2026-05-05 showed adjusted EPS $0.22 vs $0.14 consensus and sales $182.2M vs $170.0M consensus.
• The whole distribution was one gap. From the 2026-04-13 close of roughly $14.53 to the $25.00 consideration — a 72.1% premium — the re-rating printed in the 2026-04-14 session (shares +69%). The three months that followed paid only the residual settlement spread.

Bear Case

• There is nothing to trade. Regular-way NYSE trading in AVNS was suspended on 2026-07-27; the company requested delisting via Form 25 and is now a wholly owned subsidiary of A-AV Holdco I, Inc.
• Any AVNS quote still visible on a screen is a stale final print. The last reference close in the split/dividend-adjusted daily series was $24.99 on 2026-07-24, against a 52-week high of $25.05 — those numbers no longer update.
• Public disclosure ends. The Form 10-Q for the quarter ended 2026-03-31 (CIK 0001606498) is the last quarterly report on EDGAR; deregistration removes the reporting obligation, so there is no future print against which any fundamental view could be graded. (Inference, from the going-private structure — not a filed statement.)
• Symbol reuse is a live contamination risk for anything mechanical. Exchanges recycle tickers; a future AVNS price series would belong to a different issuer, and a screen keying on ticker rather than listing status would silently splice two unrelated companies.

Setup & Price Structure

The last completed daily close was $24.99 on 2026-07-24, 0.2% below the 52-week high of $25.05 — roughly a four-basis-point discount to the $25.00 consideration, which is settlement mechanics rather than a market opinion. Three-month return into that date: 1.3%. RSI(14) printed 76.9, an artifact of the 2026-04-14 gap from ~$14.53 rather than evidence of demand; the same distortion produced Benzinga's 2026-05-04 "may collapse this month" screen at RSI 90. Moving averages, breakout shelves and oscillators carried no information on a contractually pinned price and now have no series behind them at all. On positioning, the observable worth recording is index-mechanical: S&P Dow Jones Indices announced on 2026-07-20 that V2X would replace AVNS in the S&P SmallCap 600 before the open on 2026-07-27, which forced passive deletion into the same session that trading stopped. The residual holder base into the close was merger arbitrage collecting a spread measured in days.

Catalyst Calendar (next 30 days)

• None. No earnings date, no shareholder meeting, no regulatory decision and no scheduled corporate event exists for a private company. The Q2 report that would have landed in early August 2026 was never filed as a public company.
• Post-close administrative filings (Form 25 / Form 15 deregistration) are housekeeping and carry no economic content.

Elapsed catalysts

• 2026-07-27 (elapsed) — merger completion, NYSE trading suspension, Form 25 delisting request. This was the terminal dated event in the name. (passed 30d ago)

What Would Change Our Mind

The structure that would have to reappear is a listing. Nothing about Avanos's business, guidance or multiple can move this read, because no security references it: the only development that reopens analysis is regular-way AVNS trading resuming on a US exchange, which would imply either an unwound merger — for which there is no evidence — or the reassignment of the symbol to an unrelated issuer. Stated in gradeable form: a daily close below $25.00 in a legitimate AVNS series would indicate something other than a completed $25.00 all-cash merger, and no such print can exist while the company is held privately by AIP. A secondary condition that would demand a fresh look is a Delaware appraisal petition by dissenting holders that puts a per-share number other than $25.00 into the record. Absent one of those two observables, the name stays retired and this file is a historical entry.

Correlation Notes

• Live correlation is undefined after 2026-07-27. There is no return series, so beta to XLV, IHI or any small-cap benchmark cannot be computed forward.
• Pre-close the name had already decoupled from healthcare: from the 2026-04-14 announcement to the 2026-07-24 final close the stock moved 1.3% over three months while sector indices traded on their own drivers — a cash-clamped price tracks the calendar and the discount rate, not the group.
• The read-across that survives is the comp. AIP paid $1.272B EV and a 72.1% premium to the undisturbed 2026-04-13 close for a medtech running roughly $182M of quarterly sales with improving margins. That pairing of premium and multiple is the reference point for the next sponsor approach in small-cap medtech, and it is the reason RSI-driven "overbought" screens on any small-cap with an unexplained 60%+ single-session gap deserve a check of the deal tape before they are read as momentum.